Pharmaceuticals Company profiles at provigator.com |  Email This Post | View all Company profiles for Pharmaceuticals 983 views

Ranbaxy Laboratories Limited is India’s largest pharmaceutical company. Incorporated in 1961, Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. It is ranked among the top 10 generic companies worldwide. Ranbaxy went public in 1973.

Ranbaxy was started by Ranjit Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. Interestingly the name Ranbaxy is a portmanteau word from the names of its first owners Ranjit and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranjit Singh and Gurbax Singh. After Bhai Mohan Singh’s son Parvinder Singh joined the company in 1967, the company saw a significant transformation in its business and scale. His sons Malvinder Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company Daichi in June 2008.

Ranbaxy is one of the leading pharma Companies in India commanding a market share of 5.07%. (Source : ORG-IMS, March, 2007). The Company has clocked sales of USD 286 Mn (2006) registering a growth of over 17%. Growing ahead of the market the Company has enhanced its competitive position in the domestic market through its focused approach. The Company’s business has been realigned to its customer groups and investments have been made in high growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style led) as well as has reinforced its leading position in the Acute segment.
In the NDDS segment, Ranbaxy is the market leader with 7.9% market share and its NDDS product portfolio contributes to about 9% of its total turnover. Its product portfolio spans across Acute & Chronic Business covering Anti-infectives, Nutritionals, Gastro-intestinals, Pain Management ( Acute) Cardiovasculars, Dermatologicals, Central Nervous Systems (Chronic)segments.

Company’s India operations are a dominant force in a number of participating therapeutic segments, for example Anti-infectives, Statins, Dermatology and Pain Management Operations are structured into 9 Strategic Business Units. A publicly listed company, Ranbaxy India is also a member of IPA (Indian Pharmaceutical Alliance) & OPPI (Organization of Pharmaceutical Producers of India).

Amongst the pharmaceutical companies in India, Ranbaxy has the largest R&D budget with an R&D spend of over US $ 100Mn. Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 70’s. To support its global ambition, a first of its kind world class R&D centre was commissioned in 1994. Today, the Company’s multi-disciplinary R&D centre at Gurgaon, in India, houses dedicated facilities for generics research and innovative research. The Company’s robust R&D environment for both drug discovery & development reflects the Company’s commitment to be a leader in the generics space and offer value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes.

The new drug research areas at Ranbaxy include anti-infectives, inflammatory / respiratory, metabolic diseases, oncology, urology and anti-malaria. Presently, the Company has 8-10 programs comprising one anti-malaria molecule in Phase-II clinical trials. The Company has two programs in Phase I and the remaining in the pre-clinical stage. This includes a collaborative research program with GSK.

The company’s NDDS focus is mainly on the development of NDA/ANDAs of oral controlled- release products for the regulated markets. The Company’s first significant international success using the NDDS technology platform came in September 1999, when Ranbaxy out-licensed its first once-a-day formulation to a multinational company.

Corporate Office:

Ranbaxy Laboratories Limited
Corporate Office
Plot 90, Sector 32,
Gurgaon – 122001
Haryana.
India

Tel: +91-124-4135000
Fax: +91-124-4135001

List of offices

http://www.ranbaxy.com